Drug transport in HEMA conjunctival inserts containing precipitated drug particles

Gupta, Chhavi; Chauhan, Anuj

doi:10.1016/j.jcis.2010.03.037

Cited by 21 publications

(6 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, different polymeric nanocarriers based on poloxamers are widely described in the literature [25]. One example is the use of HEMA conjunctival inserts, which can be placed in the inferior conjunctival sac of the eyes as carriers of cyclosporine A for dry eye treatment [26].…”

Section: Resultsmentioning

confidence: 99%

Amphiphilic Acrylic Nanoparticles Containing the Poloxamer Star Bayfit® 10WF15 as Ophthalmic Drug Carriers

et al. 2019

View full text Add to dashboard Cite

Topical application of drops containing ocular drugs is the preferred non-invasive route to treat diseases that affect the anterior segment of the eye. However, the formulation of eye drops is a major challenge for pharmacists since the access of drugs to ocular tissues is restricted by several barriers. Acetazolamide (ACZ) is a carbonic anhydrase inhibitor used orally for the treatment of ocular hypertension in glaucoma. However, large ACZ doses are needed which results in systemic side effects. Recently, we synthesized copolymers based on 2-hydroxyethyl methacrylate (HEMA) and a functionalized three-arm poloxamer star (Bayfit-MA). The new material (HEMA/Bayfit-MA) was engineered to be transformed into nanoparticles without the use of surfactants, which represents a significant step forward in developing new ophthalmic drug delivery platforms. Acetazolamide-loaded nanocarriers (ACZ-NPs) were prepared via dialysis (224 ± 19 nm, −17.2 ± 0.4 mV). The in vitro release rate of ACZ was constant over 24 h (cumulative delivery of ACZ: 83.3 ± 8.4%). Following standard specifications, ACZ-NPs were not cytotoxic in vitro in cornea, conjunctiva, and macrophages. In normotensive rabbits, ACZ-NPs generated a significant intraocular pressure reduction compared to a conventional solution of ACZ (16.4% versus 9.6%) with the same dose of the hypotensive drug (20 µg). In comparison to previously reported studies, this formulation reduced intraocular pressure with a lower dose of ACZ. In summary, HEMA:Bayfit-MA nanoparticles may be a promising system for ocular topical treatments, showing an enhanced ocular bioavailability of ACZ after a single instillation on the ocular surface.

show abstract

Section: Resultsmentioning

confidence: 99%

Amphiphilic Acrylic Nanoparticles Containing the Poloxamer Star Bayfit® 10WF15 as Ophthalmic Drug Carriers

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The hydrogels were synthesized by free radical polymerization of HEMA monomers in the presence of a cross-linker ethylene glycol dimethacrylate (EGDMA) and photo initiator Darocur®, curing at 360-370 nm (UV irradiation) for 30 min. [25][26][27][28] If such developed therapeutic hydrogel contact lenses are placed on the eye, the HA will slowly diffuse from the lens matrix, and enter the post-lens and pre-lens tear film. The HA molecules would thus have a much longer residence time in the post-lens tear film.…”

Section: Introductionmentioning

confidence: 99%

Extended release of hyaluronic acid from hydrogel contact lenses for dry eye syndrome

Maulvi

Soni

Shah

2015

Journal of Biomaterials Science, Polymer Edition

View full text Add to dashboard Cite

Current dry eye treatment includes delivering comfort enhancing agents to the eye via eye drops, but low residence time of eye drops leads to low bioavailability. Frequent administration leads to incompliance in patients, so there is a great need for medical device such as contact lenses to treat dry eye. Studies in the past have demonstrated the efficacy of hyaluronic acid (HA) in the treatment of dry eyes using eye drops. In this paper, we present two methods to load HA in hydrogel contact lenses, soaking method and direct entrapment. The contact lenses were characterized by studying their optical and physical properties to determine their suitability as extended wear contact lenses. HA-laden hydrogel contact lenses prepared by soaking method showed release up to 48 h with acceptable physical and optical properties. Hydrogel contact lenses prepared by direct entrapment method showed significant sustained release in comparison to soaking method. HA entrapped in hydrogels resulted in reduction in % transmittance, sodium ion permeability and surface contact angle, while increase in % swelling. The impact on each of these properties was proportional to HA loading. The batch with 200-μg HA loading showed all acceptable values (parameters) for contact lens use. Results of cytotoxicity study indicated the safety of hydrogel contact lenses. In vivo pharmacokinetics studies in rabbit tear fluid showed dramatic increase in HA mean residence time and area under the curve with lenses in comparison to eye drop treatment. The study demonstrates the promising potential of delivering HA through contact lenses for the treatment of dry eye syndrome.

show abstract

“…17 Therefore, HEMA was used as the main material to construct the ring examined in the current study. Here, we examine the transconjunctival/transscleral transport of ofloxacin, a quinolone antibiotic effective in treating bacterial eye infections, to the posterior segment of the eye.…”

Section: Introductionmentioning

confidence: 99%

Hydrogel Ring for Topical Drug Delivery to the Ocular Posterior Segment

Shikamura

Yamazaki²,

Matsunaga³

et al. 2015

Current Eye Research

View full text Add to dashboard Cite

show abstract

Drug transport in HEMA conjunctival inserts containing precipitated drug particles

Cited by 21 publications

References 32 publications

Amphiphilic Acrylic Nanoparticles Containing the Poloxamer Star Bayfit® 10WF15 as Ophthalmic Drug Carriers

Amphiphilic Acrylic Nanoparticles Containing the Poloxamer Star Bayfit® 10WF15 as Ophthalmic Drug Carriers

Extended release of hyaluronic acid from hydrogel contact lenses for dry eye syndrome

Hydrogel Ring for Topical Drug Delivery to the Ocular Posterior Segment

Contact Info

Product

Resources

About